Stock Ratings / Health Care / SHPH / insiders

IMMP (60) MIRA (48) CRVO (29) CELU (34) ⌘ Pro Terminal →

Shuttle Pharmaceuticals Holdings Inc. (SHPH) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$5.23 -0.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Shuttle Pharmaceuticals Holdings Inc. (SHPH) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $24.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SHPH)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SHPH Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SHPH)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SHPH. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SHPH)

✓Walkthrough of SHPH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SHPH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.22%▲ ASCENDING CHANNEL

2026-10-30O $5.35H $5.41L $4.80C $5.23VOL 20.5K

RES: $6.14SUP: $3.36SMA50: $4.18SMA200: $7.05

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SHPH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SHPH Butterfly Map → + Track SHPH →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SHPH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SHPH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SHPH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SHPH)

Health Care Rank #460 of 1016 ⚔️ IMMP vs SHPH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SHPH vs. IMMP, MIRA, CRVO, CELU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Shuttle Pharmaceuticals Holdings Inc. (SHPH) ranks #460 by composite RQD confidence (46/100, grade D) and #819 by equity capitalization ($24.9M). Within this direct 5-issuer industry benchmark cohort, SHPH leads on earnings valuation at N/A trailing P/E, while SHPH leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IMMP currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with SHPH at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SHPH ACTIVE Shuttle Pharmaceuticals Holdings Inc.	D	46/100	—	—	-35.0%	-0.19%	$24.9M	Benchmark Subject
IMMP Immutep Limited	C-	60/100	—	—	—	+0.30%	$24.5M	/immp-vs-shph →
MIRA MIRA Pharmaceuticals Inc.	D	48/100	—	—	-35.0%	+2.79%	$24.0M	/mira-vs-shph →
CRVO CervoMed Inc.	E	29/100	—	—	-35.0%	-20.81%	$26.5M	/crvo-vs-shph →
CELU Celularity Inc. (Class A)	E	34/100	—	24.4%	-35.0%	-9.66%	$27.6M	/celu-vs-shph →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001757499

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Shuttle Pharmaceuticals Holdings Inc. (SHPH) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$11.7M, operating cash flow of -$9.5M, and free cash flow of -$9.5M (-29.4% YoY). On the balance sheet, SHPH closed FY2025 with $10.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$11.7M	-$9.5M	-$9.5M	$10.5M	—
FY2024 (FY)	2024-12-31	$0	-$9.1M	-$7.3M	-$7.3M	$2.5M	—
FY2023 (FY)	2023-12-31	$0	-$6.6M	-$5.6M	-$5.6M	—	—

3. SHPH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SHPH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Shuttle Pharmaceuticals Holdings Inc. (NASDAQ: SHPH) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $5.23 (-0.19% 1D, market cap $24.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SHPH ranks #460 in composite RQD confidence.

How does SHPH compare to IMMP and MIRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SHPH carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMMP (Immutep Limited) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $24.5M) and MIRA (MIRA Pharmaceuticals Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $24.0M). Among the 5-stock peer group, SHPH leads on earnings multiple (N/A) while SHPH leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SHPH?

Per SHPH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001757499), Shuttle Pharmaceuticals Holdings Inc. generated $0 in revenue, -$11.7M in net income, and -$9.5M in free cash flow against $10.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SHPH trading relative to its 50-day, 200-day, and 52-week technical levels?

SHPH last traded at $5.23 (-0.19% on volume of 5,572 shares), positioning the stock +25.12% above its 50-day simple moving average ($4.18) and -25.82% below its 200-day simple moving average ($7.05). Across its 52-week range of $2.58 to $44.40, SHPH sits at the 6.3% percentile with a 14-day RSI of 58.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.58 to $5.88).

SHPH Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are SHPH insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SHPH leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: SHPH RQD Cockpit SHPH 12M Forecast SHPH Earnings & Move SHPH Dividends & DRIP SHPH Insiders & 13F SHPH Whale Options SHPH Profit Sankey SHPH News & Why